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Abstract 
Objectives: To evaluate the association between metastasis-inducing protein S100A4 and 
disease activity in patients with rheumatoid arthritis (RA), and to demonstrate the effect of 
TNFα blocking therapy on plasma levels of S100A4 in these patients. 
Methods: Plasma levels of the S100A4 protein were analysed in 40 anti-TNFα-naive patients 
with active RA. Of the 40 patients, 25 were treated with adalimumab and monitored over 
time. The conformational form of S100A4 was analysed using size-exclusion gel 
chromatography. TNFα mRNA expression and protein synthesis were analysed by RT-PCR 
and ELISA, respectively. 
Results: Baseline levels of S100A4 were significantly correlated with disease activity in RA 
patients (r=0.41, p0.01). After 12 weeks of treatment with adalimumab, there was an 
obvious shift in the conformations of S100A4 from the multimeric to the dimeric forms; 
whereas the total levels of the S100A4 protein remained unchanged. This suggests that the 
bioactive (multimer) S100A4 may decline in response to successful treatment with 
adalimumab. In addition, we showed significant up-regulation of TNFα mRNA (p<0.01), and 
protein release to the cell culture medium of monocytes stimulated with the S100A4 multimer 
compared to those treated with the dimer and to the unstimulated monocytes (p<0.001).  
Conclusions: This is the first study to show that the levels of the S100A4 protein are 
correlated with RA disease activity. Furthermore, only the bioactive form, but not the total 
amount of S100A4, decreases after successful TNFα blocking therapy in patients with RA. 
These data support an important role for the S100A4 multimer in the pathogenesis of RA. 
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Introduction 
Rheumatoid arthritis (RA) is a systemic, autoimmune, inflammatory disease characterised by 
persistent inflammation of synovial joints and progressive joint destruction. The exact 
etiopathogenesis of RA is still uncertain. Nevertheless, several different cell types, such as T 
cells, B cells, macrophages and synovial fibroblasts have been shown to produce a wide range 
of cytokines and inflammatory mediators that contribute to the tissue-destructive process of 
the disease [1-3]. Tumour necrosis factor-α (TNFα), which is secreted by most of these cells, 
is one of the central drivers of RA‘s pathology [4,5]. As a result, TNFα inhibitors have been 
introduced as an effective treatment for patients with active RA [6,7].  
 
The S100 protein family represents the largest group of calcium-binding proteins, and it is 
known to be involved in diverse biological regulatory activities [8]. The best-known members 
of the family, S100A8/A9 and S100A12, have been localised to inflammation sites and 
proposed to act as alarmins – endogenous molecules that signal tissue and cellular damage 
[9,10]. S100 alarmins can be released, exert cytokine-like activities, and trigger a variety of 
intracellular signalling pathways [9,10]. Both S100A8/A9 and S100A12 have been previously 
found to be up-regulated in inflamed synovial tissue, in synovial fluid and in circulating blood 
of patients with RA. In addition, a tight association between these proteins and the activity of 
the disease has been recently demonstrated in patients with several arthritides [11-14]. 
Furthermore, the levels of both alarmins decrease in response to different anti-inflammatory 
therapies and become up-regulated even weeks before the clinical appearance of relapse in 
patients with previously well-controlled disease [15,16]. In addition, the decline in both S100 
proteins in the synovial tissue and in the bloodstream has also been demonstrated in RA 
patients who were treated with the TNFα inhibitors infliximab or etanercept [14,16,17].  
 
We have recently reported that another member of the S100 family, S100A4, is significantly 
up-regulated in activated synovial fibroblasts, in hyperplastic synovial tissue, and in synovial 
fluid and plasma of RA patients [18-21]. S100A4, also known as calvasculin, fibroblast 
specific protein (FspI) or metastasin (Mts1), was first described 20 years ago as a metastasis-
specific gene product [22]. Since then, it has become evident that S100A4 contributes not 
only to the regulation of tumour progression and metastasis [for review see ref. 23], but that it 
may also participate in the process of inflammation and cartilage destruction [24, 25].  
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Therefore, the aim of this study was to evaluate the association between the S100A4 protein 
and disease activity, and to measure the effect of the TNFα inhibitor adalimumab on the 
plasma levels of S100A4 protein in patients with active RA.  
 
Methods 
Patients  
Forty patients with active RA were enrolled in this study (34 females and 6 males, mean 
[±SD] age 50.6 ± 13.3 years). All patients fulfilled the revised criteria of the American 
College of Rheumatology (ACR) for the diagnosis of RA [26]. Twenty five of these patients, 
(21 females and 4 males, mean age 43.7 ± 10.3 years) were treated with the anti-TNFα agent 
adalimumab and then followed for the following 12 weeks. Adalimumab was administrated 
subcutaneously in a standard dose of 40 mg every other week. The mean dose of methotrexate 
and glucocorticoids did not differ during the treatment. The disease activity of RA patients 
was assessed according to the 28 joint count Disease Activity Score (DAS28) using the 
number of swollen and tender joints, erythrocyte sedimentation rate (ESR) and patient’s 
global visual analogue scale (VAS) [27]. Baseline characteristics of the patients are provided 
in table 1. The study was approved by the local ethics committee and informed consent was 
obtained from all patients.  
 
Laboratory analyses 
Blood samples were collected from all patients at baseline and, additionally, from the 
adalimumab group at weeks 6 and 12 after therapy initiation. Samples were immediately 
centrifuged and stored at -20°C until analysis. CRP was analysed by latex 
immunoturbidimetric assay according to the manufacturers’ protocol (Olympus). Plasma 
S100A4 concentration was measured by a sandwich ELISA, as previously described [21].  
 
Size-exclusion gel filtration chromatography (SEC) was carried out using a Superdex 200 PC 
3.2/30 column (Amersham Biosciences) with buffer A (50 mM Tris- HCl pH 7.4, 144 mM 
NaCl) as the mobile phase. The column was calibrated using a gel filtration standard (Bio-Rad 
Laboratories) ranging from 1.35 to 670 kDa. The mixture included thyroglobulin (670kDa), 
bovine gamma-globulin (158 kDa), chicken ovalbumin (44 kDa), equine myoglobin (17 kDa), 
and vitamin B12 (1.35 kDa). A plasma volume of 20 μl was applied to the column. The 
chromatography profile was monitored at 215 nm. Fractions of 50 μl were collected, snap-
frozen in liquid nitrogen and stored at -80°C. 
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Stimulation of monocytes by S100A4 
Human peripheral blood mononuclear cells were isolated from the peripheral blood of healthy 
volunteers (n=4) by Ficoll-Plaque density gradient centrifugation. CD14 + monocytes were 
selected positively using anti-CD14 microbeads (Miltenyi Biotec). Monocytes were plated at 
5.0 × 105 cells (confluent cells condition) per 2 mL of advanced RPMI medium 1640 
(Invitrogen) supplemented with L-glutamine (Gibco) in 35 mm-diameter culture plates. After 
plating, monocytes were incubated for 30min at 37°C with 5% CO2 in a humidified 
atmosphere. Non-adherent cells were eliminated by sterile PBS wash. Adherent cells were 
treated with a S100A4 dimer (1μg/ml) and multimer (1μg/ml) for 6 and 24 hours. The 
S100A4 proteins were obtained from recombinant His6-tagged protein by gel filtration [28]. 
The dose and time course were selected in accordance with our previous experiments [19,21]. 
The incubation was terminated after 6 hours and cells were lysed by RLT buffer (Qiagen) and 
stored in -80°C until RNA isolation. Cell culture supernatants were collected after 24 hours of 
exposure to S100A4 and stored in -20°C. 
 
RT-PCR analysis 
Total RNA from monocytes was extracted using the MagNA Pure Compact RNA Isolation kit 
for MagNA Pure Compact Instrument (Roche Diagnostics GmbH, Germany). Complementary 
DNA was obtained by reverse transcription using RevertAidTM First Strand cDNA Synthesis 
Kit (Fermentas Life Sciences, Lithuania). Polymerase chain reaction (PCR) was performed 
according to a standard protocol. Pre-developed commercially available primers (Applied 
Biosystems) were used to detect TNFα mRNA. The 18S Ribosomal RNA was used to 
normalise the results. Data were analysed using the comparative threshold cycle (Ct) method 
for relative quantification, and the Ct for 18S samples was subtracted from the Ct of the 
studied genes, giving the dCt values. Real-time PCR was performed using the 7900HT Fast 
Real-Time PCR System (Applied Biosystems). 
 
Enzyme-linked immunosorbent assay 
The levels of TNFα were measured in the cell culture supernatants using an ELISA kit 
according to the manufacturer’s protocol (Ray Biotech, Inc., Norcross GA). The analysis was 
performed using a SUNRISE ELISA reader (Tecan, Salzburg, Austria) at a wavelength of 450 
nm. 
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 Statistical analyses 
S100A4 protein concentrations were expressed as mean (± SEM). Spearman’s rank 
correlation was used to correlate any two variables. The Friedman analysis of variance test for 
repeated measures and Mann-Whitney test for comparisons between two measures were 
performed. For all statistical evaluations, p values below 0.05 were considered statistically 
significant. 
 
Results  
S100A4 protein and disease activity  
Disease activity decreased significantly after treatment with adalimumab (mean ± SD - 
DAS28: 6.2 ± 0.7 (baseline) vs. 3.8 ± 1.0 (week 6) vs. 3.3 ± 0.9 (week 12); p<0.01). The 
treatment was clinically effective in 23 out of 25 RA patients (delta DAS28: ≥ 1.2). The 
baseline level of S100A4 in plasma correlated strongly with the baseline DAS28 (r=0.41, 
p0.01) (Fig.1). However, no correlations were observed between the S100A4 protein and the 
DAS28 at weeks 6 and 12 after the initiation of therapy, as well as between the baseline 
S100A4 and the change in DAS28 between baseline and week 12 (r=0.23, p=0.26). Levels of 
S100A4 protein did not correlate with the baseline levels of CRP (r=-0.17, p=0.29), IgM 
rheumatoid factor (r=0.02, p=0.9) or with anti-citrullinated protein/peptide antibodies (ACPA) 
(r=0.09, p=0.56). Likewise, these variables did not correlate with S100A4 levels after the 
treatment (data not shown). Results were indicative of a relationship between S100A4 protein 
and the inflammatory activity, rather than with the autoimmune response of the disease. 
 
The effect of TNF inhibitor adalimumab on the plasma S100A4 protein  
S100A4 values in plasma of healthy individuals are normally in the range of 50-300 ng/ml 
(mean 80 ng/ml), as reported in our previous study [21]. As shown in figure 2A, the total 
plasma levels of S100A4 were significantly higher, but not significantly affected by 
adalimumab treatment (mean ± SEM, baseline vs. week 6 vs. week 12: 466.4 ± 66.5 vs. 522.1 
± 58.4 vs. 535.1 ± 96.8 ng/ml) in patients with RA. Plasma samples from eight randomly 
selected patients were subjected to SEC, and six of them demonstrated a tendency to shift 
from the high to the low conformational form after 12 weeks of adalimumab therapy. Two 
representative profiles of the SEC are shown in figures 2B and 2C. One of the two samples 
showing no clear conformational shift in S100A4 belonged to a patient who failed to achieve 
a clinically effective response (Fig. 2D). Patients responding to the treatment with 
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adalimumab showed a clear shift in the conformations of S100A4 from the multimeric and 
oligomeric forms to the dimeric forms. In contrast, no such clear shift was observed in a 
patient who experienced an inadequate response to the treatment with adalimumab. This 
patient presented, instead, a tendency for an increase in some multimeric and oligomeric 
S100A4 forms. Therefore, it can be suggested that successful treatment of RA patients yields 
the prompt conformational modifications of the bioactive S100A4 multimer toward the less 
bioactive S100A4 dimer. 
 
S100A4 multimer up-regulates TNF in human monocytes  
To confirm the bioactivity of the S100A4 multimer, we stimulated peripheral blood 
monocytes with the S100A4 multimer and dimer. We then analysed the levels of TNF 
mRNA after 6 hours of treatment and the levels of TNF in supernatants after 24 hours. Four 
independent experiments were performed in duplicates. The expression of TNF mRNA was 
up-regulated by more than three times in monocytes treated with the S100A4 multimer 
compared to monocytes exposed to the S100A4 dimer (p<0.01) (Fig.3A). In addition, the 
synthesis of TNF by monocytes was significantly increased in those samples treated with the 
S100A4 multimer for 24 hours, when compared to monocytes stimulated with the S100A4 
dimer and to unstimulated monocytes (4474.6±1282 vs. 958.4±706.2 vs. 250.3±165 pg/ml; 
p<0.001) (Fig. 3B). 
 
 
 
Discussion 
This study shows, for the first time, that the levels of the metastasis-inducing protein S100A4 
are significantly correlated with the disease activity of RA. In addition, we also showed that 
after successful TNF-blocking therapy with adalimumab, there is a significant decrease in 
the bioactive S100A4 multimer, with no concomitant change in the total amount of S100A4 
protein. 
 
S100A4 protein has been mostly studied in cancers, particularly with respect to its ability to 
enhance metastasis [23]. In addition, recent data has linked S100A4 to the pathogenesis of 
RA. We have demonstrated the up-regulation of S100A4 in the synovium, synovial fluid and 
bloodstream of patients with RA. We have also shown that this protein has a regulatory role 
 8
within several pathogenic aspects of the disease [19-21]. In contrast with other S100 proteins, 
S100A4 was not restricted to phagocytes, but also co-localised with fibroblasts, several 
immune cells and vascular cells [21]. The abundance of S100A4 in synovial tissue and 
synovial fluid from patients with RA was consistent with the finding of high concentrations of 
the protein in RA, compared with the osteoarthritis/control plasma samples [21]. 
Consequently, we have shown, for the first time, a significant association between the 
S100A4 concentration and the RA disease activity. Our finding is consistent with the data 
presented by Foell et al. [12] and Wulffraat et al. [13], who found an association between 
other S100 proteins (S100A12 and S100A8/9) and disease activity in patients with RA. 
Furthermore, an association of S100A8/9 with autoantibodies, including rheumatoid factor or 
ACPA, has been previously documented [29]. Nevertheless, we have found no significant 
correlation between S100A4 and rheumatoid factor or ACPA antibodies. We have also not 
found any correlation between S100A4 protein and CRP. Thereby, it can be suggested that 
S100A4 reflects the disease activity as assessed by all the components of DAS28 rather than 
the acute phase response or the immune activation only.  
 
It has been previously demonstrated that the concentration of S100A8/9 and S100A12 
decrease significantly both at the local and global (bloodstream) levels in patients with RA, 
following TNFα-blocking therapy [14,16,17]. Therefore, we expected changes in the 
plasmatic S100A4 levels after TNFα-blocking therapy. Surprisingly, TNFα-blocking with 
adalimumab did not change plasma levels of the total S100A4 protein. S100A4 can exist as a 
multimer or as a dimer. Several studies have demonstrated that the dimer form of S100A4 
resides intracellularly. In contrast, the multimeric conformations, which are the biologically 
active forms of S100A4 and which can therefore trigger several cellular responses, reside 
mostly extracellularly. [28,30]. By analysing the conformation of the S100A4 protein, we 
observed a conformational shift from the bioactive multimers to the less active, oligomeric 
and dimeric forms following adalimumab therapy. To confirm the bioactivity of the S100A4 
multimer [28,30], we demonstrated that when compared with the dimer,  the S100A4 
multimer, considerably up-regulated TNFα gene expression and protein release by activated 
monocytes. These results are in agreement with our previous reports showing that only the 
S100A4 multimer, but not the dimer, was capable of modulating the expression of matrix-
degrading enzymes and apoptotic molecules in synovial fibroblasts [19,21]. Since multimers 
are considered biologically active, we hypothesise that the down-regulation of the bioactive 
S100A4 protein (multimer) could be associated with the improvement in disease activity 
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observed after TNFα-blocking therapy. Moreover, our unpublished “in vitro” data with 
synovial fibroblasts correspond well to the results of Devoogdt et al. [31] in cancer cells, 
which suggested that TNFα does not change the expression of S100A4 mRNA. In addition, 
S100A4 mRNA is up-regulated in monocytes from patients with RA, compared with healthy 
controls. However, S100A4 mRNA does not appear to be modulated by TNFα in human 
monocytes [Oslejskova, unpublished data]. Thus, we suggest that S100A4 is regulated 
independently of TNFα, and/or by posttranslational modification, depending on the 
inflammatory activity of the disease.  
 
This study has some limitations. We have not correlated the levels of S100A4 protein with the 
measures of joint damage. Therefore, we could not postulate the potential predictive value of 
S100A4 for further development of the disease, as demonstrated recently for calprotectin 
[29,32]. It is not yet possible to quantify the S100A4 multimer and associate this form with 
the disease activity of RA, a relationship that could be extremely informative. Moreover, this 
study was designed to analyse the association of S100A4 with the disease activity of RA and 
did not include healthy controls for comparison. However, our previous results have 
demonstrated a significant increase in plasma S100A4 levels in patients with RA, compared 
with control individuals [21].  
 
In conclusion, we have demonstrated for the first time, that the levels of the metastasis-
inducing protein S100A4, similar to alarmins S100A8/9 and S100A12, are significantly 
correlated with RA disease activity. Furthermore, we have showed that the bioactive S100A4 
multimer, but not the total amount of S100A4, declines after successful TNF-blocking 
therapy.  
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Table 1: Baseline characteristics of the patients with rheumatoid arthritis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Subgroup of RA patients treated with anti-TNFα  
All RA patients - anti-
TNF naive 
 
number 
 
gender (F/M) 
 
age (years) 
 
CRP (mg/l) 
 
DAS28 score 
 
drugs 
(MTX/GC) 
 
ESR 
(mm/1st h) 
 
S100A4 
(ng/ml) 
 
 
25 
 
21/4 
 
43.7 ± 10.3 
 
38 ± 28.9 
 
6.2 ± 0.7 
 
19/16 
 
 
39.8 ± 20.1 
 
 
       466.5 ± 306.1 
 
 
40 
 
34/6 
 
50.6 ± 13.3 
 
29.9 ± 26.5 
 
5.8 ± 1.2 
 
28/27 
 
 
34.3 ± 20.1 
 
 
          592 ± 458.3 
 16
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RA, rheumatoid arthritis; F, female; M, male; MTX, methotrexate; GC, 
glucocorticoids; DAS, disease activity score; CRP, C-reactive protein; ESR, 
erythrocyte sedimentation rate. 
S100A4 concentrations are expressed as mean ± SEM. 
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Figure legends: 
 
Figure 1 Relationship between the baseline disease activity and plasma levels of the 
metastasis-inducing protein S100A4 in patients with rheumatoid arthritis. 
 
Figure 2 Modulation of metastasis-inducing protein S100A4 plasma levels in rheumatoid 
arthritis patients in response to the TNF inhibitor adalimumab. Total plasma levels of S100A4 
remained unchanged during the therapy (A). An obvious shift occurred in S100A4 from the 
high to the low molecular weight form, together with a decline in the bioactive S100A4 
multimer after 12 weeks of the therapy with adalimumab (B, C). However, no clear 
conformational shift of S100A4 from the high to the low (dimeric) molecular weight, but 
rather a tendency for an increase of some multimeric and oligomeric S100A4 forms, was 
documented in a patient who experienced an inadequate response to the treatment with 
adalimumab. The representative profile of the S100A4 conformational modulation is depicted 
(D).  
The numbers on the x-axis represent 13 fractions of S100A4 with different molecular weights 
(kDa) separated by size-exclusion chromatography. Each fraction corresponds to a certain 
S100A4 conformation, for instance fr.#13=2mer, fr.#11=4mer, fr.#9=14mer, fr.#5 = >60 mer. 
Trend-lines are indicated. 
 
 
Figure 3 Increased expression of TNFα mRNA in human monocytes treated with the S100A4 
multimer for 6 hours compared with monocytes exposed to the S100A4 dimer (A). 
Monocytes treated with S100A4 multimer for 24 hours significantly enhanced TNFα release 
into the cell culture medium compared to monocytes stimulated with S100A4 dimer and 
unstimulated monocytes (B). Results of TNFα gene expression expressed as fold increases 
with respect to the expression of TNFα mRNA in unstimulated monocytes. Data are obtained 
from four independent experiments performed in duplicates. 
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Key messages 
The levels of the metastasis-inducing protein S100A4 in plasma correlates with RA disease 
activity  
Bioactive S100A4 multimer, but not the total amount of S100A4, declines after successful 
TNF-blocking therapy 
S100A4 multimer up-regulates TNFα gene expression and protein release by activated 
monocytes “in vitro” 
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